$SLNO
SOLENO THERAPEUTICS INC

2021 Q3 Form 10-Q Financial Statement

#000156459021056228 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q4 2020 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.767M $2.250M $2.000M
YoY Change 22.43% 39.75% -0.5%
% of Gross Profit
Research & Development $4.968M $5.570M $6.695M
YoY Change 2.86% 5.69% 142.57%
% of Gross Profit
Depreciation & Amortization $492.0K $480.0K $490.0K
YoY Change 0.41% -2.04% 0.0%
% of Gross Profit
Operating Expenses $8.286M $7.820M $9.282M
YoY Change 16.87% 13.66% 86.46%
Operating Profit -$8.286M -$9.282M
YoY Change 86.46%
Interest Expense $34.00K $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $112.0K $5.110M $3.424M
YoY Change -116.28% -164.93% -266.86%
Pretax Income -$8.140M -$2.850M -$5.860M
YoY Change -4.8% -80.52% -16.64%
Income Tax
% Of Pretax Income
Net Earnings -$8.140M -$2.850M -$5.858M
YoY Change -4.8% -80.52% -16.67%
Net Earnings / Revenue
Basic Earnings Per Share -$1.53
Diluted Earnings Per Share -$102.0K -$35.75K -$131.2K
COMMON SHARES
Basic Shares Outstanding 5.319M 44.69M
Diluted Shares Outstanding 5.319M

Balance Sheet

Concept 2021 Q3 2020 Q4 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.19M $49.22M $15.07M
YoY Change -49.8% 137.43% -25.36%
Cash & Equivalents $28.20M $49.22M $15.07M
Short-Term Investments
Other Short-Term Assets $702.0K $1.020M $570.0K
YoY Change 100.57% 148.78% -5.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $28.89M $50.24M $15.64M
YoY Change -48.86% 137.62% -25.04%
LONG-TERM ASSETS
Property, Plant & Equipment $555.0K $19.00K $370.0K
YoY Change 141.3% -13.64% 1847.37%
Goodwill
YoY Change
Intangibles $14.58M
YoY Change -11.76%
Long-Term Investments
YoY Change
Other Assets $40.00K $15.00K $60.00K
YoY Change -74.58%
Total Long-Term Assets $13.68M $14.74M $16.47M
YoY Change -10.57% -13.44% -8.51%
TOTAL ASSETS
Total Short-Term Assets $28.89M $50.24M $15.64M
Total Long-Term Assets $13.68M $14.74M $16.47M
Total Assets $42.57M $64.98M $32.11M
YoY Change -40.7% 70.23% -17.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.858M $3.489M $3.480M
YoY Change 20.07% 74.89% 176.63%
Accrued Expenses $4.692M $4.930M $3.500M
YoY Change 7.12% 90.35% 253.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.042M $8.618M $7.290M
YoY Change 13.08% 73.61% 224.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $13.32M $10.82M $60.00K
YoY Change -15.59% 7260.54% -99.54%
Total Long-Term Liabilities $13.32M $10.82M $60.00K
YoY Change -15.59% 7260.54% -99.54%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.042M $8.618M $7.290M
Total Long-Term Liabilities $13.32M $10.82M $60.00K
Total Liabilities $22.36M $19.44M $22.63M
YoY Change -5.96% -16.32% 48.53%
SHAREHOLDERS EQUITY
Retained Earnings -$210.5M -$182.4M
YoY Change 17.21% 15.61%
Common Stock $228.0M
YoY Change 31.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.20M $45.55M $9.481M
YoY Change
Total Liabilities & Shareholders Equity $42.57M $64.98M $32.11M
YoY Change -40.7% 70.23% -17.38%

Cashflow Statement

Concept 2021 Q3 2020 Q4 2020 Q1
OPERATING ACTIVITIES
Net Income -$8.140M -$2.850M -$5.858M
YoY Change -4.8% -80.52% -16.67%
Depreciation, Depletion And Amortization $492.0K $480.0K $490.0K
YoY Change 0.41% -2.04% 0.0%
Cash From Operating Activities -$5.406M -$6.860M -$5.659M
YoY Change -12.38% 35.04% 53.49%
INVESTING ACTIVITIES
Capital Expenditures -$5.000K -$10.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$5.000K -$10.00K $0.00
YoY Change -110.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -40.00K -4.000K
YoY Change -100.0% -100.28%
NET CHANGE
Cash From Operating Activities -5.406M -6.860M -5.659M
Cash From Investing Activities -5.000K -10.00K 0.000
Cash From Financing Activities 0.000 -40.00K -4.000K
Net Change In Cash -5.411M -6.910M -5.663M
YoY Change -15.05% -172.74% 53.18%
FREE CASH FLOW
Cash From Operating Activities -$5.406M -$6.860M -$5.659M
Capital Expenditures -$5.000K -$10.00K $0.00
Free Cash Flow -$5.401M -$6.850M -$5.659M
YoY Change -12.46% 34.84% 53.07%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
9481000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
45547000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
341000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
40000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15000
CY2020Q2 slno Issuance Of Common Stock Value Under Equity Incentive Plans
IssuanceOfCommonStockValueUnderEquityIncentivePlans
17000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
906000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
79791075
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-8140000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-5858000
CY2020Q4 us-gaap Liabilities
Liabilities
19435000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
80000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
227912000
CY2020Q4 us-gaap Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
10278000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
274000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-182445000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
79583254
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
79744807
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
56916137
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1095000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Income Tax Deficiency From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation
-120000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
37568000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
857000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-10988000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
27437000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-8954000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-317000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
40000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
369000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-196000
slno Increase Decrease In Accrued Clinical Trial Site Costs
IncreaseDecreaseInAccruedClinicalTrialSiteCosts
-196000
slno Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-156000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
299000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20907000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
53760000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
120000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
3000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
581000
slno Deferred Financing Costs Included In Accounts Payable
DeferredFinancingCostsIncludedInAccountsPayable
38000
us-gaap Net Income Loss
NetIncomeLoss
-28100000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-210500000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28200000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20900000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
600000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
300000
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.09
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P20M
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
100296
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
334320
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
179100
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
613716
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
49592
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
564124
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
81000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
76000
us-gaap Operating Lease Cost
OperatingLeaseCost
235000
us-gaap Operating Lease Cost
OperatingLeaseCost
229000
CY2020Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
4000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
7000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1000
CY2020Q3 slno Finance Lease Cost
FinanceLeaseCost
2000
slno Finance Lease Cost
FinanceLeaseCost
4000
slno Finance Lease Cost
FinanceLeaseCost
8000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
906000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
374000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2858000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1107000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.004
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.84
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.73
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.89
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7152860
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10291891

Files In Submission

Name View Source Status
0001564590-21-056228-index-headers.html Edgar Link pending
0001564590-21-056228-index.html Edgar Link pending
0001564590-21-056228.txt Edgar Link pending
0001564590-21-056228-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
slno-10q_20210930.htm Edgar Link pending
slno-10q_20210930_htm.xml Edgar Link completed
slno-20210930.xsd Edgar Link pending
slno-20210930_cal.xml Edgar Link unprocessable
slno-20210930_def.xml Edgar Link unprocessable
slno-20210930_lab.xml Edgar Link unprocessable
slno-20210930_pre.xml Edgar Link unprocessable
slno-ex311_9.htm Edgar Link pending
slno-ex312_8.htm Edgar Link pending
slno-ex321_7.htm Edgar Link pending
slno-ex322_6.htm Edgar Link pending